Design of Peptidomimetic Functionalized Cholesterol Based Lipid Nanoparticles for Efficient Delivery of Therapeutic Nucleic Acids
Open Access
- 19 September 2019
- Vol. 24 (18) , 3413
Abstract
Lipid nanoparticles (LNP) are the most potent carriers for the delivery of nucleic acid-based therapeutics. The first FDA approved a short interfering RNA (siRNA) drug that uses a cationic LNP system for the delivery of siRNA against human transthyretin (hTTR). However, preparation of such LNP involves tedious multi-step synthesis with relatively low yields. In the present study, we synthesized cationic peptidomimetic functionalized cholesterol (denote Chorn) in straightforward chemical approaches with high yield. When formulated with helper lipids, Chorn LNPs complexed with siRNA to form nanoparticles with an average diameter of 150 nm to 200 nm. Chorn LNP mediated transfection of a green fluorescence protein (GFP) expressing plasmid resulted in 60% GFP positive cells. Moreover, Chorn LNP delivered siRNA against polo-like kinase 1 (Plk1), a disease related gene in cancer cells and efficiently suppressed the expression of the gene, resulting in significant morphological changes in the cell nuclei. Our data suggested that cholesterol based cationic LNP, prepared through a robust chemical strategy, may provide a promising siRNA delivery system.Keywords
Funding Information
- National Natural Science Foundation of China (81560568, 21875124)
This publication has 32 references indexed in Scilit:
- Silencing or Stimulation? siRNA Delivery and the Immune SystemAnnual Review of Chemical and Biomolecular Engineering, 2011
- Design and Assembly of New Nonviral RNAi Delivery Agents by Microwave-Assisted Quaternization (MAQ) of Tertiary AminesBioconjugate Chemistry, 2010
- Efficient siRNA delivery into primary cells by a peptide transduction domain–dsRNA binding domain fusion proteinNature Biotechnology, 2009
- RNAi therapeutics: Principles, prospects and challengesAdvanced Drug Delivery Reviews, 2007
- Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acidsJournal of Controlled Release, 2005
- Potent and persistent in vivo anti-HBV activity of chemically modified siRNAsNature Biotechnology, 2005
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAsNature, 2004
- Visualizing a Correlation between siRNA Localization, Cellular Uptake, and RNAi in Living CellsChemistry & Biology, 2004
- siRNA function in RNAi: A chemical modification analysisRNA, 2003
- A novel cationic liposome reagent for efficient transfection of mammalian cellsBiochemical and Biophysical Research Communications, 1991